Prof F. Van Gompel, ITG Antwerpen

More documents

Recommendations

Info

Meningococcal conjugate vaccine Significant decline in antibody 3 to 5 years after vaccination Few cases of MD among vaccinated persons Revaccination for persons at risk Vaccination with a single dose not sufficient in complement deficiency, asplenia, HIV, young children 2 doses 2 months apart MMWR, jan 2011
MCV-4 booster 3 years after initial vaccination : convenience sample from MCV-4 and PSV-4 groups with vaccine-naive comparison Geometric mean serum bactericidal antibody titers Day 28 Serogroup MCV-4 PSV-4 A C Y W-135 4326 8192 5846 4612 3270 665 2327 1577 H. Keyserling, Arch Pediatr Adolesc Med 2005 (Menactra)
Page 1 and 2: 9 th National Seminar on Travel Med
Page 3 and 4: Worldwide distribution of major men
Page 5 and 6: Transmission : person to person By
Page 7: Travlrs risk of MD Like general pop
Page 10 and 11: CDC, Pink Book 2011
Page 12 and 13: 2009 = 2010 = 2011
Page 14 and 15: Travlrs risk of MD 1986-1989 13 ca
Page 16 and 17: Travlrs risk of MD Hajj pilgrims (
Page 18 and 19: Quadrivalent polysaccharide vaccine
Page 21 and 22: Jackson PIDJ 2009
Page 23 and 24: % ≥1:8 hSBA Persistence of Protec
Page 25: MMWR, aug 2011 (ACIP)
Page 30 and 31: 2009 =2010= 2011
Page 34 and 35: 8. Meningococcal vaccine: Mencevax
Page 37 and 38: UK Green Book 2010 Chapter 22 pages
Page 39 and 40: Menveo ® Folia Pharmacotherapeutic
Page 41 and 42: Menveo ® Folia Pharmacotherapeutic
Page 43 and 44: CDC yellow book 2012 • CDC recomm

Prof F. Van Gompel, ITG Antwerpen

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?